|Bid||5.00 x 1100|
|Ask||5.11 x 1100|
|Day's Range||4.94 - 5.34|
|52 Week Range||3.74 - 28.18|
|Beta (5Y Monthly)||1.37|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Tricida (TCDA) has been struggling lately, but the selling pressure may be coming to an end soon
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...
Shares of Tricida (NASDAQ: TCDA) are down 30% at 1:33 p.m. EST today after the Food and Drug Administration denied the company's appeal of a complete response letter (CRL) that the agency issued for Tricida's marketing application for veverimer as a treatment for chronic kidney disease. A CRL, like the one Tricida received in August 2020, is essentially a rejection letter from the FDA with instructions on what data the agency would need to see for the drug to eventually get approved. Tricida was trying to get veverimer approved under the accelerated approval pathway, which uses surrogate endpoints, such as biomarkers, to predict clinical outcomes.